Sac-TMT + Pembrolizumab NSCLC Trial Published

Sichuan Kelun-Biotech Biopharmaceutical>>> announced the publication of positive Phase III clinical study results for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab as a first-line treatment for PD-L1-positive non-small cell lung cancer (NSCLC) in The Lancet. The OptiTROP-Lung05 study demonstrated that the combination significantly prolonged progression-free survival (PFS) and showed a positive trend in overall survival (OS) compared to pembrolizumab monotherapy, with a manageable safety profile. This marks the first Phase III trial of an antibody-drug conjugate (ADC) combined with an immune checkpoint inhibitor to meet its primary endpoint in first-line NSCLC treatment. The findings were also selected for an oral presentation at the 2026 American Society of Clinical Oncology>>> Annual Meeting. Sac-TMT, a core product of Sichuan Kelun-Biotech Biopharmaceutical>>> with proprietary intellectual property rights, targets various advanced solid tumors. In May 2022, Sichuan Kelun-Biotech Biopharmaceutical>>> licensed exclusive rights for sac-TMT outside Greater China>>> to MSD, a subsidiary of Merck & Co.>>>. Sac-TMT has already received approval for four indications in China>>> and has been included in China>>>'s National Reimbursement Drug List. The China — National Medical Products Administration>>> has granted sac-TMT six Breakthrough Therapy Designations and accepted a new indication application for sac-TMT in combination with pembrolizumab for priority review.